- Home
- LULU vs JAZZ Comparison
LULU vs JAZZ Comparison
Compare LULU & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LULU | JAZZ |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 15.0B |
| IPO Year | 2007 | 2007 |
Fundamental Metrics
Financial Performance| Metric | LULU | JAZZ |
|---|---|---|
| Price | $111.84 | $223.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 25 | 14 |
| Target Price | $190.26 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 3.9M | 765.4K |
| Earning Date | 06-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.69 | ★ 4.43 |
| Revenue | ★ $11,102,600,000.00 | $1,618,693,000.00 |
| Revenue This Year | $5.52 | $6.22 |
| Revenue Next Year | $4.68 | $7.68 |
| P/E Ratio | $65.62 | ★ $50.77 |
| Revenue Growth | ★ 4.86 | N/A |
| 52 Week Low | $109.36 | $105.00 |
| 52 Week High | $252.24 | $243.32 |
Technical Indicators
Market Signals| Indicator | LULU | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 45.70 |
| Support Level | $109.36 | $224.23 |
| Resistance Level | $170.94 | $242.66 |
| Average True Range (ATR) | 4.93 | 6.87 |
| MACD | -0.36 | -2.13 |
| Stochastic Oscillator | 10.55 | 18.45 |
Price Performance
Historical ComparisonAbout LULU lululemon athletica inc.
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 800 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 45 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.